首页> 外文期刊>Bone marrow transplantation >Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation.
【24h】

Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation.

机译:无关供体同种异体造血干细胞移植成功治疗Griscelli综合征。

获取原文
获取原文并翻译 | 示例
       

摘要

Griscelli syndrome (GS) is a rare autosomal recessive disorder, characterized by pigmentary dilution of the skin and hair and in most patients by abnormal regulation of the immune system, which results in a syndrome of macrophage hyperactivation, known as hemophagocytic lymophohistiocytosis (HLH). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for genetically induced HLH. Few cases of successful HSCT from a compatible donor have been reported in children with GS. We describe the first patient with GS cured with an allograft from a compatible unrelated bone marrow donor. We used a novel preparative regimen consisting of busulfan, thiotepa and fludarabine. The demonstrated curative effect of HSCT from an unrelated donor in a patient with genetically determined HLH also supports the use of a systematic diagnostic approach in these patients, in order to identify those with a worse prognosis and needing an urgent allograft in a timely manner.
机译:Griscelli综合征(GS)是一种罕见的常染色体隐性遗传疾病,其特征是皮肤和头发的色素稀释,并且在大多数患者中免疫系统异常调节,导致巨噬细胞过度活化综合征,称为噬血细胞性淋巴组织细胞增生症(HLH)。异基因造血干细胞移植(HSCT)是可用于基因诱导HLH的唯一治疗方法。 GS患儿中很少有从兼容的供体成功获得HSCT的病例报道。我们描述了第一例由兼容的无关骨髓供体同种异体移植治愈的GS患者。我们使用了由白消安,噻替帕和氟达拉滨组成的新型制备方案。在遗传确定的HLH患者中,来自不相关供体的HSCT的疗效证明也支持在这些患者中使用系统的诊断方法,以便确定预后较差并需要紧急同种异体移植的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号